The Future of Genomic Testing in the Canadian Health Care Landscape: Overcoming Challenges & Embracing Opportunities for a Path Forward

The Biomarkers Conference, held on June 19-20, 2025, was a remarkable success, drawing over 600 registrants from across Canada and beyond. The event united a diverse group of clinicians, pathologists, researchers, patients, caregivers, advocates, policy professionals, and industry leaders, exemplifying our shared commitment to advancing biomarker testing and precision oncology.

Participants actively engaged in insightful presentations and collaborative panel discussions led by leading experts. The Conference featured lively Q&A sessions, reflecting a high level of interaction and enthusiasm among participants. Our most anticipated session was a hit: the keynote presentation led by the Conference Board of Canada (CBoC) shared their insightful comprehensive genomic profiling (CGP) cost benefit analysis findings commissioned by CCRAN. This presentation set the stage for impactful discussions during the clinician and patient advocacy group roundtables, as well as for future advocacy efforts.

Attendee feedback was overwhelmingly positive, highlighting the vital role the Conference serves in fostering knowledge exchange, collaboration, and advocacy for equitable access to CGP for metastatic cancer patients in Canada, an essential step toward personalized cancer care, as reflected in one participant’s heartfelt comment: “As a patient, it's so wonderful to see the passion and dedication by so many medical professionals.”

CCRAN extends our sincere gratitude to everyone who contributed to the success of the 2025 Biomarkers Conference, including our sponsors, supporting patient advocacy groups, Steering Committee, and expert speakers. Your dedication and collaboration were instrumental in making this event possible and highly successful.

Building on this momentum, we eagerly anticipate next year’s Conference, which promises to expand in scope and impact. Stay tuned for exciting developments as we continue to drive innovation and improve outcomes for patients through biomarker research and integration.